Substance P(1-7) (TFA) constitutes the N-terminal segment of Substance P, retaining key aromatic and basic residues that influence structural dynamics. Researchers use it to examine peptide-protein interfaces, β-turn formation, and solvent effects. The sequence provides insight into truncated peptide behavior. The TFA form allows predictable solvation for assays.
CAT No: R2205
CAS No:2828433-22-1
Synonyms/Alias:Substance P(1-7) (TFA);Substance P(1-7) TFA;2828433-22-1;(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoic acid;2,2,2-trifluoroacetic acid;1-7-Substance P trifluoroacetate;HY-P1485A;MS-31866;CS-0046306;G16494;
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
3. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
5. Myotropic activity of allatostatins in tenebrionid beetles
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More